Sun Pharma Announces the Availability of UNLOXCYTâ„¢ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
3 days ago
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC…